Mark C. Heit

674 total citations
17 papers, 511 citations indexed

About

Mark C. Heit is a scholar working on Pharmacology, Molecular Biology and Pharmaceutical Science. According to data from OpenAlex, Mark C. Heit has authored 17 papers receiving a total of 511 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Pharmacology, 4 papers in Molecular Biology and 4 papers in Pharmaceutical Science. Recurrent topics in Mark C. Heit's work include Advancements in Transdermal Drug Delivery (4 papers), Lipid Membrane Structure and Behavior (4 papers) and Antibiotics Pharmacokinetics and Efficacy (3 papers). Mark C. Heit is often cited by papers focused on Advancements in Transdermal Drug Delivery (4 papers), Lipid Membrane Structure and Behavior (4 papers) and Antibiotics Pharmacokinetics and Efficacy (3 papers). Mark C. Heit collaborates with scholars based in United States, Canada and Italy. Mark C. Heit's co-authors include Jim E. Riviere, Friederike L. Jayes, Millagahamada G. Ranasinghe, Ted Whittem, Kirby Pasloske, Patrick Williams, Martin Guillot, Éric Troncy, Maxim Moreau and Jean‐Pierre Pelletier and has published in prestigious journals such as Pharmaceutical Research, Journal of Pharmaceutical Sciences and Neuropharmacology.

In The Last Decade

Mark C. Heit

17 papers receiving 484 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark C. Heit United States	11	179	178	78	64	63	17	511
Claude A. Piché United States	17	253 1.4×	87 0.5×	57 0.7×	6 0.1×	79 1.3×	24	828
Philippe Gruet France	15	145 0.8×	13 0.1×	47 0.6×	18 0.3×	111 1.8×	19	580
Timothy W. Morgan United States	14	55 0.3×	31 0.2×	58 0.7×	9 0.1×	72 1.1×	27	489
Guy Bouchard United States	11	139 0.8×	10 0.1×	20 0.3×	17 0.3×	59 0.9×	22	348
Christophe A. Rème France	13	39 0.2×	32 0.2×	28 0.4×	226 3.5×	43 0.7×	21	381
John E. Harkness United States	4	96 0.5×	9 0.1×	13 0.2×	10 0.2×	56 0.9×	5	356
Robert A. Kennis United States	11	51 0.3×	14 0.1×	15 0.2×	109 1.7×	41 0.7×	24	339
Gustavo Calvo Argentina	9	258 1.4×	3 0.0×	81 1.0×	6 0.1×	44 0.7×	15	481
Zlatko Pavlica Slovenia	11	21 0.1×	38 0.2×	13 0.2×	5 0.1×	130 2.1×	28	431
Karl A. Andrutis United States	9	149 0.8×	3 0.0×	21 0.3×	4 0.1×	106 1.7×	12	598

Countries citing papers authored by Mark C. Heit

Since Specialization

Citations

This map shows the geographic impact of Mark C. Heit's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark C. Heit with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark C. Heit more than expected).

Fields of papers citing papers by Mark C. Heit

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark C. Heit. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark C. Heit. The network helps show where Mark C. Heit may publish in the future.

Co-authorship network of co-authors of Mark C. Heit

This figure shows the co-authorship network connecting the top 25 collaborators of Mark C. Heit. A scholar is included among the top collaborators of Mark C. Heit based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark C. Heit. Mark C. Heit is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

1.

Heit, Mark C., Katrina L. Mealey, & Stephen King. (2021). Tolerance and Pharmacokinetics of Galliprant™ Administered Orally to Collies Homozygous for MDR1‐1Δ. Journal of Veterinary Pharmacology and Therapeutics. 44(5). 705–713. 5 indexed citations

2.

Heit, Mark C., et al.. (2020). Safety evaluation of the interchangeable use of robenacoxib in commercially-available tablets and solution for injection in cats. BMC Veterinary Research. 16(1). 355–355. 2 indexed citations

3.

Toutain, Céline E., et al.. (2017). Safety evaluation of the interchangeable use of robenacoxib (Onsior™) tablets and solution for injection in dogs. BMC Veterinary Research. 13(1). 359–359. 9 indexed citations

4.

Klinck, Mary P., Margaret E. Gruen, Jérôme R. E. del Castillo, et al.. (2017). Development and preliminary validity and reliability of the montreal instrument for cat arthritis testing, for use by caretaker/owner, MI-CAT(C), via a randomised clinical trial. Applied Animal Behaviour Science. 200. 96–105. 13 indexed citations

5.

Guillot, Martin, Maxim Moreau, Mark C. Heit, et al.. (2013). Characterization of osteoarthritis in cats and meloxicam efficacy using objective chronic pain evaluation tools. The Veterinary Journal. 196(3). 360–367. 84 indexed citations

6.

Clark, M., Karl Thomaseth, Mark C. Heit, & Margarethe Hoenig. (2011). Pharmacokinetics and pharmacodynamics of protamine zinc recombinant human insulin in healthy dogs. Journal of Veterinary Pharmacology and Therapeutics. 35(4). 342–350. 11 indexed citations

7.

Whittem, Ted, Kirby Pasloske, Mark C. Heit, & Millagahamada G. Ranasinghe. (2008). The pharmacokinetics and pharmacodynamics of alfaxalone in cats after single and multiple intravenous administration of Alfaxan^®at clinical and supraclinical doses. Journal of Veterinary Pharmacology and Therapeutics. 31(6). 571–579. 89 indexed citations

8.

Heit, Mark C., Douglas Smith, & R.P. Enever. (1998). Site-specific Drug Delivery in the Dog using Flexible Fiberoptic Endoscopy. Journal of Pharmaceutical Sciences. 87(10). 1209–1212. 1 indexed citations

9.

Vaden, Shelly L., et al.. (1997). Fluconazole in cats: Pharmacokinetics following intravenous and oral administration and penetration into cerebrospinal fluid, aqueous humour and pulmonary epithelial lining fluid. Journal of Veterinary Pharmacology and Therapeutics. 20(3). 181–186. 38 indexed citations

10.

Riviere, Jim E. & Mark C. Heit. (1997). Electrically-Assisted Transdermal Drug Delivery. Pharmaceutical Research. 14(6). 687–697. 110 indexed citations

11.

Heit, Mark C. & J. E. Riviere. (1995). Antifungal therapy: ketoconazole and other azole derivatives. Compendium on Continuing Education for The Practicing Veterinarian. 7 indexed citations

12.

Heit, Mark C., et al.. (1994). Isoelectric Focusing and Capillary Zone Electrophoretic Studies Using Luteinizing Hormone Releasing Hormone and Its Analog. Journal of Pharmaceutical Sciences. 83(5). 654–656. 10 indexed citations

13.

Heit, Mark C., Nancy A. Monteiro‐Riviere, Friederike L. Jayes, & Jim E. Riviere. (1994). Transdermal lontophoretic Delivery of Luteinizing Hormone Releasing Hormone (LHRH): Effect of Repeated Administration. Pharmaceutical Research. 11(7). 1000–1003. 30 indexed citations

14.

Heit, Mark C., et al.. (1993). Transdermal lontophoretic Peptide Delivery: In Vitro and In Vivo Studies with Luteinizing Hormone Releasing Hormone. Journal of Pharmaceutical Sciences. 82(5). A240–A243. 44 indexed citations

15.

Heit, Mark C., et al.. (1993). Transdermal lontophoretic Peptide Delivery: In Vitro and In Vivo Studies with Luteinizing Hormone Releasing Hormone. Journal of Pharmaceutical Sciences. 82(3). 240–243. 37 indexed citations

16.

Heit, Mark C.. (1988). Pharmacological studies with a GABA uptake inhibitor in rats with kindled seizures in the amygdala. Neuropharmacology. 27(4). 367–374. 18 indexed citations

17.

Heit, Mark C. & Wayne S. Schwark. (1987). An efficient method for time course studies of antiepileptic drugs using the kindled rat seizure model. Journal of Pharmacological Methods. 18(4). 319–325. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact